 |
|
|
|
 |
|
|
| Article 1 to 10 out of 41 concerning National Institutes of Health (NIH)
|
-
NIH extends agreement with Galapagos
(07/23/2008)
Galapagos NV announced that the U.S. National Institutes of Health (NIH) have extended their agreement with Galapagos' service division BioFocus DPI for the operation of the Molecular Libraries Small Molecule Repository (MLSMR) until December 2010. ...
-
Metagenomics of skin reveals insights into the human microbiome
(05/23/2008)
The human body is home to a diverse range of microorganisms, estimated to outnumber human cells in a healthy adult by ten fold. The importance of characterizing human microbiota for understanding health and disease is highlighted by the recent ...
-
Diamyd executes agreement with US National Institutes of Health for a type 1 diabetes trial
(11/27/2007)
Diamyd Medical announced that it has executed a Clinical Trial Agreement with the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) for a planned clinical study with the DiamydŽ GAD-alum diabetes vaccine in 126 new onset type ...
-
Cytori awarded NIH Grant to develop cell-based treatments for vascular disease
(09/21/2007)
Cytori Therapeutics was awarded a $250,000 NIH (National Institutes of Health) Grant to develop adipose-derived regenerative cells as a treatment for vascular disease.Regenerative cells within adipose (fat) tissue include adult stem cells and other ...
-
Agilent Technologies Tools Used to Derive New Type of Mouse Embryonic Stem Cell that Shares Key Features of Human Embryonic Stem
(07/30/2007)
Using a variety of Agilent Technologies genomics tools, researchers at the National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH), and the University of Oxford, U.K., have achieved a major milestone in ...
-
Pharmexa and Bavarian Nordic initiate new NIH funded Phase I trial of HIV vaccines in combination
(05/03/2007)
Pharmexa-Epimmune and Bavarian Nordic announced the initiation of a Phase I trial testing two HIV vaccines EP1233 and MVA-BN Polytope in combination. The clinical trial will be conducted by the HIV Vaccine Trials Network (HVTN) which is supported ...
-
Ariadne Receives SBIR Phase I Grant from NIH
(03/19/2007)
Ariadne announced receiving a $100,000 SBIR Phase I grant from the NIH, National Center for Research Resources towards the further development of MedScan technology. MedScan employs natural language processing (NLP) to extract biomedical information ...
-
NIH and Santhera Announce Positive Results of Study with SNT-MC17/idebenone in Friedreich's Ataxia (FRDA)
(11/14/2006)
The US National Institute of Neurological Disorders and Stroke (NINDS) at the National Institutes of Health (NIH) presented results of their recently completed clinical trial with SNT-MC17/idebenone in Friedreich's Ataxia (FRDA). This six month ...
-
Crucell Secures $16.2 million NIH Contract for HIV Vaccine Design and Development
(10/10/2006)
Crucell N.V. announced that it has secured a US$ 16.2 million contract from the National Institute of Allergy and Infectious Diseases, part of the U.S. National Institutes of Health (NIH), for the design and development of an HIV vaccine. The ...
-
NIH Completes Collaborative Phase II Study with Santhera's compound SNT-MC17/idebenone in Friedreich's Ataxia (FRDA)
(10/09/2006)
The US National Institute of Neurological Disorders and Stroke (NINDS) at the National Institutes of Health (NIH) and Santhera Pharmaceuticals completed their six month double-blind placebo-controlled Phase II clinical trial with SNT-MC17/idebenone ...
|
|
|
|
|
Top